| |
|
|
|
| Unsafe Drugs
:: Vytorin
|
VYTORIN - Ezetimibe/simvastatin is more commonly known as Vytorin or Inegy. It is a combination of the statin Zocor and the cholesterol-lowering drug Zetia, which is marketed as a joint venture by the pharmaceutical giants Merck & Co. and Schering-Plough. It was first introduced to the market as a method to block cholesterol build up and the absorption of cholesterol in the system. It is proclaimed to inhibit the enzyme HMG-CoA reductase required by the body to create cholesterol, though recent studies seriously question the drug's effectiveness.
Side effects of Vytorin are myopathy (muscle weakness), myalgia (muscle pain), Rhabdomyolysis (a breakdown of skeletal tissues), abdominal pain, hepatitis, angeioedema (swelling of the skin, underlying tissues, and mucous membranes), fatigue, eczema, headaches, depression, or upper respiratory infections. In recent studies, serious links to cancer have been attributed to Vytorin as well as a connection to fatal heart failure due to a narrowing of the aortic valve. When taking Vytorin, it is important to be alert for signs of an allergic reaction that causes angeioedema. Swelling of the face, nasal passages, or throat can accelerate into a deadly emergency in minutes and needs to be dealt with swiftly.
Many of the known side effects of Vytorin can create major difficulties in the everyday lives of the patients who use it. Job loss, family stress, loss of relationships, neglect, and other issues affecting patients who take this drug have a tremendous impact on the quality of life they and their families lead. The fatal side effects of Vytorin cause serious grief and distress to family members and may leave them without not only a father or mother, or husband or wife, but a provider as well.
If you or a loved one have taken the prescription drugs Vytorin or Inegy, and have been diagnosed with cancer or suffered a heart condition possibly associated with Vytorin or Inegy, it is important to seek legal counsel immediately. Litigating cases against powerful pharmaceutical companies is complex and expensive. You need expert advice and guidance for a successful outcome.
Fill out the form below for a free evaluation by a law firm that has the resources and experience handling unsafe pharmaceutical cases.
Keywords: Vytorin Lawsuit | Vytorin Attorney | Vytorin Lawyer | Vytorin Attorneys | Vytorin Lawyers
|
| Free Case Evaluation |
Use the form below to submit your case and receive a free evaluation. By submitting this form, you certify that you agree to our Terms and Conditions and want us to contact you regarding your inquiry. Required fields are marked in BOLD.
|
| Vytorin In the News |
Drug to Cut Cholesterol Is Approved by the FDA - New York Times
Medical DailyDrug to Cut Cholesterol Is Approved by the FDANew York TimesA clinical trial of more than 18,000 patients is assessing whether Vytorin significantly reduces heart attacks, strokes and heart-related deaths and is...
More Information »
Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist ... - PR Newswire (press release)
Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist ...PR Newswire (press release)Over a career that has spanned more than three decades, Dr. MacDonald has brought hundreds of drug candidates into...
More Information »
Statin Users May Have a Reason to Rejoice After This Data - Motley Fool
Statin Users May Have a Reason to Rejoice After This DataMotley FoolThese results are actually pretty similar to that of Vytorin (Merck's combination drug of Zocor and Zetia), which reduced LDL-cholesterol by 45% to 60%,...
More Information »
“Marketing Without Innovation”: a Merck Story - YCharts
“Marketing Without Innovation”: a Merck StoryYChartsThe FDA approved Liptruzet, which is a combination of Zetia and atorvastatin, which is the active ingredient in Lipitor – the Pfizer (PFE) drug that is now widely available...
More Information »
Can Merck's Pipeline Offset The Pain From Major Patent Expirations? - Trefis
Can Merck's Pipeline Offset The Pain From Major Patent Expirations?TrefisThe silver lining is that the FDA had granted breakthrough status to Lambrolizumab in April, which is an investigational PD-1 specific monoclonal...
More Information »
Merck's CEO Discusses Q1 2013 Results - Earnings Call Transcript - Seeking Alpha
Merck's CEO Discusses Q1 2013 Results - Earnings Call TranscriptSeeking AlphaWe are looking forward to having more detailed discussions with the FDA on these agents. Last week, we announced that .... In our cholesterol...
More Information »
Merck In-Licenses from Xenon - Analyst Blog - NASDAQ
Merck In-Licenses from Xenon - Analyst BlogNASDAQCurrently marketed drugs for the treatment of cardiovascular disease in Merck's portfolio are Zetia and Vytorin. Global sales of ... Merck expects to file a New Drug...
More Information »
默沙东降胆固醇新药Liptruzet获FDA批准 - 生物谷
默沙东降胆固醇新药Liptruzet获FDA批准生物谷默沙东已经在销售一种重磅降胆固醇复合药物Vytorin，该药由Zetia和默沙东的降LDL老药Zocor（舒降之，simvastatin，辛伐他汀）组成。2012年，Vytorin的销售额达17.5亿美元，Zetia的销售额则达到了26.7亿美元。Lipitor(阿托 ...
More Information »
FDA TÜKÜRDÜĞÜNÜ YALADI - Haber X
Haber XFDA TÜKÜRDÜĞÜNÜ YALADIHaber XMerck' in ezetimibe ile simvastatin birleşimi olan Vytorin isimli ilacı on senedir kalp hastalıkları riskini azalttığına dair bir delil olmamasına rağmen şakır şakır satılıyor....
More Information »
İLACI DEĞİL HAPI YUTUYORUZ - Haber X
Haber XİLACI DEĞİL HAPI YUTUYORUZHaber XKalp krizlerini önlediğini gösteren hiçbir araştırma olmamasına rağmen Zetia ve Vytorin' in (ezetimibe + simvastatin) son 7 sene içindeki satış rakamı, inanılır gibi değil ama 21...
More Information »
忘掉过去，颓废的默克急需重振创新传统 - 福布斯中国
福布斯中国忘掉过去，颓废的默克急需重振创新传统福布斯中国但是，《福布斯》杂志在2007年披露，默克公司与其伙伴先灵葆雅公司一直回避分析抗胆固醇药物葆至能（Vytorin）的试验结果。但试验的最终结果显示， ... 今年2月，公司对外宣布仍需再等一年，才向美国食品药品管理局（FDA）登 ...
More Information »
2013年美国生物医药保健企业排行榜【图】 - md.tech-ex.com
2013年美国生物医药保健企业排行榜【图】md.tech-ex.com1月14日，中国国家药监局通知称，强生视力健公司报告舒日、亮眸两款隐形眼镜因包装问题进行召回；1月30日，FDA宣布强生AVEENO品牌一款婴儿舒缓乳液细菌超标，强生随后主动召回2000支；2月15日，强生旗下o'steen ...
More Information »
리피토 제네릭 '제티아 복합제' 승인미 FDA, 머크의 콜레스테롤제 ...'립트루젯' 효과 ... - 의약뉴스
리피토 제네릭 '제티아 복합제' 승인미 FDA, 머크의 콜레스테롤제 ...'립트루젯' 효과 ...의약뉴스머크는 이미 다른 콜레스테롤 치료제인 바이토린(Vytorin)을 판매하고 있는데 이 약은 제티아와 LDL 콜레스테롤 저하 약물인 조코(Zocor, simvastatin)와의 복합제이다. 립트루젯에 포함된 리피토의 화학 성분은 아토르바스타틴(atorvastatin)으로...
More Information »
|
|
| |